Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.6400
+0.0332 (5.47%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Nektar Therapeutics Revenue
In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth. Nektar Therapeutics had revenue of $29.18M in the quarter ending December 31, 2024, with 22.15% growth.
Revenue (ttm)
$98.43M
Revenue Growth
+9.22%
P/S Ratio
1.33
Revenue / Employee
$1,613,557
Employees
61
Market Cap
118.44M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NKTR News
- 4 weeks ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 5 weeks ago - Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 weeks ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 7 weeks ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - PRNewsWire
- 7 weeks ago - Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - PRNewsWire
- 7 weeks ago - Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th - PRNewsWire
- 2 months ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - PRNewsWire